(Reuters) – A U.S. Centers for Disease Control and Prevention advisory panel voted unanimously on Sunday to recommend Johnson & Johnson’s COVID-19 shot for widespread use, and U.S. officials said initial shipments would start on Sunday.
Providing a final clearance for the vaccine a day after it was authorized by U.S. regulators, the Advisory Committee on Immunization Practices (ACIP) voted 12-0 to recommend the vaccine from J&J as appropriate for Americans 18 and older. There was one abstention due to prior conflicts of interest.
“We believe today’s recommendation from the CDC to begin use of our vaccine as part of the U.S. national immunization program will add a critical tool in the fight against COVID-19,” Paul Stoffels, J&J’s chief scientific officer, said in a statement.
To continue reading please click here